When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MRK - IMV's DPX-Survivac shows encouraging action in mid-stage DLBCL study
Merck & Company Inc.
Updated results from a Phase 2 clinical trial, SPiReL, evaluating IMV's (NASDAQ:IMV) lead candidate DPX-Survivac, combined with low-dose cyclophosphamide and Merck's (NYSE:MRK) Keytruda (pembrolizumab), in patients with persistent or relapsed/refractory diffuse large B-cell lymphoma (DLBCL) showed a positive effect.
More news on: IMV Inc., Merck & Co., Inc., Healthcare stocks news,